Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01606462
Other study ID # OXT-071/10
Secondary ID
Status Completed
Phase Phase 1
First received May 23, 2012
Last updated December 2, 2014
Start date June 2011
Est. completion date June 2013

Study information

Verified date December 2014
Source University Hospital, Bonn
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Board, Universtiy of Bonn
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether oxytocin influences memory of social stimuli and reaction to social stimuli. Furthermore the investigators explore the effect of oxytocin receptor (OXTR) polymorphism in terms of behavioral and neural responses to social stimuli.


Description:

The prevailing view of OXT as a key facilitator of prosocial behaviors has been highly influenced by a plethora of studies in healthy volunteers, which demonstrated increased interpersonal trust, generosity, social learning/empathy and positively biased social stimulus processing as a result of OXT treatment. However, this interpretation is challenged by observations that OXT also promotes envy and schadenfreude (gloating), ethno-centrism (including prejudice, xenophobia, and racial bias), and defensive aggression towards outsiders.We investigate the neural correlates of emotion perception and subsequent memory effects of aversive and neutral stimuli. Tthe oxytocin effect on personal space is questioned. Additionally the effect of OXTR polymorphism regarding behavioral and neural response is explored.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date June 2013
Est. primary completion date June 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

- Healthy male volunteers

Exclusion Criteria:

- Current or past psychiatric disease

- Current or past physical illness

- Psychoactive medication

- Tobacco smokers

- MRI contraindication

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Oxytocin
intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT

Locations

Country Name City State
Germany Department of Psychiatry, University of Bonn Bonn

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bonn

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary neural correlates of emotion perception and subsequent memory effects of aversive and neutral stimuli MRI data are analyzed using SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK). In the first level analysis the following conditions are modeled: 'neutral: subsequently remembered', 'neutral: subsequently forgotten', 'aversive: subsequently remembered', and 'aversive: subsequently forgotten'. two years No
Secondary the effect of oxytocin receptor (OXTR) polymorphism in terms of behavioral and neural responses to social stimuli behavioral social testing, fMRI analysis using SPM8, OXTR genotyping two years No
Secondary The oxytocin effect on social behavior e.g. personal space is questioned behavioral testing e.g. personal space two years No
See also
  Status Clinical Trial Phase
Completed NCT05523687 - AME Study of [14C]-PC14586 in Healthy Male Participants Phase 1
Completed NCT02250976 - The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Phase 1
Completed NCT01948011 - Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules Phase 1
Completed NCT04086719 - An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. Phase 1
Completed NCT03686501 - D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 Early Phase 1
Terminated NCT01965301 - First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 Phase 1
Completed NCT01005160 - Drug Interaction Between CKD-501 and Metformin Phase 1
Completed NCT04534582 - Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects Phase 1
Recruiting NCT06159101 - A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects Phase 1
Completed NCT01549743 - The Pharmacokinetic Interaction Between Celecoxib and Rebamipide Phase 1
Completed NCT03532854 - Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802 Phase 1
Recruiting NCT03530228 - A Phase 1 Study of Tegoprazan on Healthy Male Volunteers Phase 1
Completed NCT01356043 - CKD-828 Drug Interaction Study (S-amlodipine) Phase 1
Completed NCT04810533 - The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers Phase 1
Completed NCT03089112 - Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501 Phase 1
Completed NCT01939639 - The Influence of Oxytocin on the Processing of Social Contact Phase 1
Completed NCT01342055 - Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers Phase 1
Terminated NCT03863587 - Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects Phase 1
Completed NCT01356017 - CKD-828 Drug Interaction Study (Telmisartan) Phase 1
Completed NCT01382017 - Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study N/A